Drug Profile
Alecmestencel-T
Alternative Names: MSC Minaris Regenerative Medicine; MSC_Minaris Regenerative MedicineLatest Information Update: 06 Jan 2021
Price :
$50
*
At a glance
- Originator Apceth
- Class Mesenchymal stem cell therapies; Vascular disorder therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Peripheral arterial occlusive disorders
Most Recent Events
- 03 Dec 2018 Discontinued - Phase-II for Peripheral arterial occlusive disorders in Germany (IV)
- 17 Sep 2015 Phase-II clinical trials in Peripheral arterial occlusive disorders in Germany (IV)
- 12 Jul 2013 Alecmestencel-T is available for licensing as of 12 Jul 2013. http://www.apceth.com/home/